FDA Approves POMALIDOMIDE — Camber Pharmaceuticals, Inc.

# FDA Approves Generic Pomalidomide; Camber Pharmaceuticals Entry Expected to Intensify Competition Camber Pharmaceuticals, Inc. received FDA approval for its generic pomalidomide oral formulation (ANDA210236), marking another entrant into the competitive multiple myeloma treatment market and potentially reducing costs for patients relying on this immunomodulatory drug. The approval is anticipated to pressure pricing for the branded version while expanding patient access to this critical cancer therapy.